Using bacteriophages with antibiotics to treat infective endocarditis
Official title: A Prospective Interventional Randomized Placebo-controlled Multicenter Clinical Trial of the Efficacy, Tolerability and Safety of Phage Therapy in Combination With Standard Antibiotic Therapy in Patients With Infective Endocarditis
Run by University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) · NCT06870409 · Data updated 2026-11-12
This study is testing whether using a special virus called bacteriophages along with antibiotics can help people with a serious heart infection called infective endocarditis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) Academic / other |
| Locations | 1 site (Moscow) |
| Status | Recruiting |
| Started | February 5, 2025 |
| Main results expected | February 5, 2028 |
| Study ends | February 5, 2029 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT06870409 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are hospitalized patients with a confirmed diagnosis of active infective endocarditis.
✕Probably not a fit
Patients with inactive infective endocarditis or those undergoing immunosuppressive therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of bacteriophages in conjunction with antibiotics for patients suffering from infective endocarditis, a serious heart infection caused by bacteria. The study aims to address the growing issue of antibiotic resistance by utilizing bacteriophages, which are viruses that specifically target and kill bacteria. Participants will be hospitalized patients diagnosed with active infective endocarditis, and the trial will assess the effectiveness of this combined treatment approach. The methodology includes monitoring the efficacy of bacteriophage therapy alongside standard antibiotic treatment.
Why it matters
Potential benefit: If successful, this approach could provide a novel and effective treatment option for patients with antibiotic-resistant infections.
How similar studies have gone: While bacteriophage therapy is a relatively novel approach, previous studies have shown promise in treating antibiotic-resistant infections, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalisation with active IE or active IE developed in hospital; * Definite diagnosis of IE according to modified Duke 2023 criteria or possible diagnosis of IE but managed and treated as IE; * Informed consent to participate in the study; Exclusion Criteria: * Inactive (transferred) IE * Non-bacterial thrombotic endocarditis * Active oncological diseases * Immunosuppressive therapy
Where it's running
-
University Clinical Hospital named after V.V.Vinogradov (branch) of the Peoples' Friendship University of Russia named after Patrice Lumumba
Moscow, Russia Recruiting
Study contacts
- Study coordinator: Zhanna Davidovna Kobalava, Head of Internal Disease Unit
- Email: zkobalava@mail.ru
- Phone: +7(985)7848454
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Barts Endocarditis Registry
This registry collects health, imaging, microbiology, treatment, and outcome information from adults with infective endocarditis seen at Barts Heart Centre to learn which approaches work best.
-
Immediate reimplantation of cardiac devices after infection removal
This study is testing whether putting heart devices back in right away after an infection is safer and more effective than waiting to do it later for patients with endocarditis and device infections.
-
Using fosfomycin to treat severely infected patients
This study is testing if an intravenous antibiotic called fosfomycin can safely help people with serious infections like osteomyelitis and bacterial meningitis feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.